Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04692831 · ClinicalTrials.gov registry record · Phase 1
Testing a New Imaging Agent to Identify Cancer
A Phase 1 study of HER2-positive Metastatic Breast Cancer and HER-2 Protein Overexpression, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 8
- Study locations
NCT04692831 is a Phase 1 study of HER2-positive Metastatic Breast Cancer and HER-2 Protein Overexpression that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 60 participants, below the 119-participant average among 11 other HER2-positive Metastatic Breast Cancer trials with a reported enrollment target (50% lower). The trial reports 8 study locations across 3 states.
The verdict
NCT04692831, a Phase 1 study of HER2-positive Metastatic Breast Cancer and HER-2 Protein Overexpression, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to see whether 89Zr-ss-pertuzumab is safe in people with HER2+ cancer.
Conditions Studied
Interventions
- COMBINATION_PRODUCT 89Zr-ss-pertuzumab PET/CT
Study Locations (8)
New York
- Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activites) - Rockville Centre
New Jersey
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited protocol activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
California
- PATTY AND GEORGE HOAG CANCER CENTER (Data or Specimen Analysis Only) - Newport Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2020-11-30 |
| Est. Completion | 2026-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04692831
The ClinicalTrials.gov registry entry for NCT04692831 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 119-participant average among 11 other HER2-positive Metastatic Breast Cancer trials with a reported enrollment target (50% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with HER2-positive Metastatic Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which 89Zr-ss-pertuzumab PET/CT is the first listed.
NCT04692831 reports 8 study locations spanning 3 distinct geographic areas - top geographies include New York, New Jersey, California.
Frequently Asked Questions
What is clinical trial NCT04692831 about?
NCT04692831 is a clinical study titled "Testing a New Imaging Agent to Identify Cancer". The purpose of this study is to see whether 89Zr-ss-pertuzumab is safe in people with HER2+ cancer.
What is the current status of trial NCT04692831?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2020-11-30. Estimated completion is 2026-11-30.
What conditions does trial NCT04692831 study?
This clinical trial studies the following conditions: HER2-positive Metastatic Breast Cancer, HER-2 Protein Overexpression, HER-2 Positive Malignant Carcinoma of Breast.
What interventions are being tested in trial NCT04692831?
The interventions under investigation include: 89Zr-ss-pertuzumab PET/CT (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04692831?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04692831 being conducted?
This trial has 8 study locations across California, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-positive Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PRE-I-SPY Phase I/Ib Oncology Platform Program
RECRUITING · Phase 1
-
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
COMPLETED · Phase 1
Explore more on PlainTrial
HER2-positive Metastatic Breast Cancer
All registered trials for this condition
HER-2 Protein Overexpression
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.